Venmax Drugs & Pharmaceuticals Limited has filed its unaudited standalone financial results for the quarter ended June 30, 2026, with the Bombay Stock Exchange and the National Stock Exchange. The filing serves as a regulatory disclosure under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency for investors regarding the company’s performance in Q1FY26.

The Board of Directors approved the financial results during a meeting held on Friday, August 7, 2026, in Hyderabad. The company has made the detailed financial statement, along with the Limited Review Report, accessible to stakeholders via its official website at www.venmaxdrugs.com . Investors can also access the documents by scanning the QR code provided in the exchange filing.

Regulatory Compliance

In accordance with Regulation 47 of the SEBI (LODR) Regulations, 2015, Venmax Drugs published newspaper advertisements containing the financial results on August 8, 2026. The advertisements appeared in “Financial Express” and “Nava Telangana.” This step ensures that the information reaches a broader audience, including retail investors who may not monitor digital channels exclusively.

Key Filing Details

The filing was signed by Venkata Rao Sadhanala, Managing Director, affirming the accuracy of the reported figures. The company’s registered office is located in Secunderabad, Telangana.

Venmax Drugs & Pharmaceuticals Limited's Board of Directors, at its meeting held on August 7, 2026, approved the unaudited standalone financial results for the quarter ended June 30, 2026, along with a Limited Review Report from statutory auditors PPKG & Co, Chartered Accountants, Hyderabad. The Board also approved the forfeiture of 7,80,001 partly paid-up Convertible Share Warrants on account of non-payment of the balance subscription amount by the concerned warrant holders.

Q1FY27 Financial Performance

Venmax Drugs and Pharmaceuticals recorded a significant year-on-year improvement in its top line and bottom line for the quarter ended June 30, 2026. Revenue from operations more than doubled to ₹247.94 lakhs from ₹121.03 lakhs in the corresponding quarter of the previous year. Total revenue, including other income of ₹0.03 lakhs, stood at ₹247.96 lakhs for the quarter. The following table presents a comparative view of key financial metrics (figures in ₹ lakhs):

Total expenses for Q1FY27 were ₹236.31 lakhs, compared to ₹117.29 lakhs in Q1FY26, with purchases of stock-in-trade being the largest component at ₹341.81 lakhs, partially offset by a favourable inventory change of ₹(116.99) lakhs. Profit before tax for the quarter was ₹11.65 lakhs, up from ₹3.74 lakhs in Q1FY26. Net profit for the period stood at ₹11.66 lakhs, against ₹3.74 lakhs in the year-ago quarter. Earnings per share (basic and diluted) improved to ₹0.10 from ₹0.07 in Q1FY26.

Balance Sheet Highlights

As at June 30, 2026, total assets stood at ₹1,682.64 lakhs, compared to ₹1,620.02 lakhs as at March 31, 2026. Current assets increased to ₹1,678.55 lakhs from ₹1,616.36 lakhs, driven primarily by a rise in inventories to ₹216.87 lakhs from ₹99.88 lakhs and other financial assets to ₹1,183.22 lakhs from ₹734.97 lakhs. Total equity improved to ₹1,500.78 lakhs from ₹1,411.62 lakhs, reflecting the period's profitability. Current liabilities declined to ₹181.80 lakhs from ₹203.34 lakhs over the same period.

Forfeiture of Share Warrants

In a significant corporate action, the Board approved the forfeiture of 7,80,001 partly paid-up Convertible Share Warrants that had been allotted on a preferential basis on March 20, 2025. The warrants were originally issued at ₹20/- per warrant, with 25% (₹5/- per warrant) collected upfront at the time of allotment and the balance 75% (₹15/- per warrant) payable upon exercise for conversion into equity shares. Of the total 1,00,25,000 warrants allotted, 92,44,999 warrants were duly converted into fully paid-up equity shares following receipt of the balance subscription amount. The remaining 7,80,001 warrants were forfeited after the respective holders failed to remit the balance amount despite demand letters and reminder notices issued by the Company.

Consequently, the upfront subscription amount of ₹39,00,005/- stands forfeited and retained by the Company. The details of the warrant holders whose warrants have been forfeited are as follows:

Following the forfeiture, the said warrants stand cancelled. The Company has stated it will deal with the forfeited warrants in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and other applicable laws.

Auditor's Conclusion

Statutory auditors PPKG & Co, Chartered Accountants (FRN: 0009655S), Hyderabad, conducted a limited review of the unaudited standalone financial results for the quarter ended June 30, 2026, in accordance with Standard on Review Engagements (SRE) 2410 issued by the Institute of Chartered Accountants of India. The auditors expressed an unmodified conclusion, stating that nothing came to their attention indicating any material misstatement or non-disclosure as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results are available on the Company's website at www.venmaxdrugs.com and on the BSE website at www.bseindia.com .